Henlius

Affordable Innovation · Reliable Quality

Patient-centric treatment for global health

Henlius Company Introduction
2025

Contents

Henlius
Overview

About Henlius

Henlius is a rapidly growing biopharmaceutical provider that develops, manufactures, and distributes leading biologics and mAb oncology treatments in abaut **60 countries around the world**, serving over **900,000 patients**. Our mission is to improve patients' lives by timely providing them with quality and affordable protein therapeutics through technical innovation and operational excellence.



Biopharmaceuticals at Global Scale

Revenues

$788 million

Core products revenue growth at 8.1% YoY

Net Profit

$112.9 million

2 years Consecutive net-profit growth

R&D Expenditure

$254 million

Investing in innovation and growth

9
Products Approved Globally

~60
Approved Countries

1,150+
GMP Commercial Batches

900,000
Patients Benefited

Milestones

2010
Henlius founded in Shanghai

2016
First facility in operation

2019
Listed on HKEX (2696.HK)



2020
First facility obtains EU GMP certification

2022
Second facility commences commercial production

2023
On a total revenue of $759 MM, the company achieved a net profit of $76.9 MM

2024
Second facility obtains U.S. GMP certification

2025
Included in MSCI Global Small Cap Indexes

2010–2019
Foundation & Platform Validation

2020–2024
Global Expansion & Innovation Acceleration

2025–Today
Global Breakthrough & Pipeline Synergy

2019
HLX01 (rituximab) launched and becomes the first biosimilar approved in China

2020
HLX02 (trastuzumab) launched in the EU & China

HLX03 (adalimumab) launched in China

2021
HLX04 (bevacizumab) launched in China

2022
Serplulimab, the world's 1st anti-PD-1 mAb in 1L SCLC, launched in China

2024
HLX02 (trastuzumab) launched in the U.S.

Neratinib launched in China

2025
Serplulimab launched in the EU

BILDYOS® (denosumab) & BILPREVDA® (denosumab) launched in the U.S. and the EU

Fovinaciclib launched in China

Now
Multiple biologics and novel assets in global clinical trials

Addressing Therapeutic Areas of Highest Demand

Primary focus:

Henlius develops biological **oncology treatments** for **cancers with the highest prevalence rates and highest clinical needs.**

Breast Cancer | Lung Cancer | Gastric Cancer | Colorectal cancer | Other solid tumors and hematology

Secondary focus:

Henlius also develops biomedicine for non-oncology disorders including:

Autoimmune | Metabolic | Ophthalmology

In-House, Top Industry Talent

Leadership team with experience at Amgen, Bayer, GSK, Roche and other leading pharmaceutical companies.

Top industry talent with expertise in pharmaceutical R&D, clinical development, manufacturing, commercialization, regulatory affairs, CMC, and quality and compliance.

Complete in-house functions for entire development chain, from discovery to research to approvals.

3,515

employees

953

R&D staff

35%

female executives

808

postgraduates

Date as of December 31, 2024

Veteran Executives

Dr. Jason Zhu

Executive Director
Chief Executive Officer

- ✓ More than 20 years in clinical research industry.
- ✓ Had cooperated with over 70 China local pharmaceutical and biotech companies and led the design and execution of over 100 phase I to IV clinical trials.
- ✓ Previously served as Founder and CEO of PPC China, Global Vice President of IQVIA, China GM of Omnicare.
- ✓ Had previously worked as a physician in Huashan Hospital.

Wei Huang
President

Kurt Yu
Chief Commercial Officer
SVP

Ping Cao
Chief Business Development Officer
SVP

Simon Hsu
Chief Technology Officer
SVP

James Guo
SVP

Jessie Li
Chief Human Resource Officer
SVP

Jijun Yuan
Chief Scientific Officer

Frank Ye
Chief Quality Officer
VP

Max Mao
Chief Financial Officer
VP

Ming Yang
VP of Immune-Oncology
Business Unit

Wallis Zeng
Vice President

Jing Li
VP of Global Product
Development

Jin Li
VP of Regulatory Affairs

Miaojie Chen
VP of Legal and Compliance

Arthur Sheng
GM of Global Strategy & PMO

Qingyu Wang
China Chief Medical Officer
GM of Clinical Development Department

Ely Benaim
U.S. Chief Medical Officer

Guangri Sun
Deputy General Manager of Oncology
Business Unit

Nancy Wang
Board Secretary
GM of Public Relations

Our Advantage

Designed for efficient, affordable, effective treatments

R&D

Comprehensive internal and whole process R&D for efficient, fast, and low-risk development

Manufacturing and Quality Control

1,150 batches of GMP commercial production delivered at global standards

Commercialization

Rising to the top through efficient and global commercialization

Comprehensive R&D

Combining investment, systems, talent, facilities and partnerships for the highest-quality innovation at all stages of research and development

Early Discovery

- Leveraging advantages in antibody technology to expand new modalities of drugs.
- Internal innovation supplemented by external licensing.
- Pipeline contains ~50 molecules in R&D. Henlius Advanced Pre-clinical platforms: Tri-specific TCE Platform, Hanjugator™ ADC Platform, HAI Club

Clinical Development

- Full-cycle management system with in-house team, unique in the biopharma industry.
- 19 clinical assets
- 30+ clinical studies

Regulatory Development

- Diversified innovation that combines industry leading in-house R&D with international development partnerships to develop and launch effective, fast, and affordable products.
- Global RA Team with in-depth knowledge of registration paths for different markets
- 6 products launched, 4 ODDs granted by FDA and EC and over 140 clinical approvals worldwide.

Henlius Advanced Platforms

Tri-specific T cell Engager



- Longer persistence of Activated T Cell
- Greater Efficacy in solid tumor Treatment
- Enhanced Safety with lower CRS Risks

Hanjugator™ ADC Platform



- Expanded clinical therapeutic window
- Overcome resistance to widely used payloads
- Combination of multiple payload mechanisms

HAI Club Platform



- Identification of Novel drug targets
- Cost-effective Research & Development
- Improved Success rate in drug discovery

Henlius Advanced Platforms

rHuPH20 1.0



- Identical sequence as Halozyme HYLENEX®
- Ideal choice for biosimilars and innovative drugs

rHuPH20 2.0

HENOZYE



- Henlius propretairy hyaluronidase
- Excellent stability and adaptable for multiple complex scenarios
- Ideal choice for innovative drugs

Formulation Development



- Development platform based on AI+ technology
- High concentration formulation development
- Co-formulation development with different types of hyaluronidase

Advanced Manufacturing & Quality Control

Competitive production capacity that meets the GMP standards from China, EU, and US

3 production facilities in Shanghai – China's tech, finance, and logistics hub

Xuhui Site

since 2019

- 24,000L commercial production capacity
- GMP-certified from China, the EU, and PIC/S members (Brazil, Indonesia)

Songjiang Site I

since 2022

- 24,000L commercial production capacity
- GMP-certified from China, the EU, and the U.S.
- ISO 14001:2015 and ISO 45001:2018 dual certifications

Songjiang Site II

Groundbreaking in 2019

- Phase I and II 36,000L capacity
- One of the largest biomedicine manufacturing facilities in China
- GMP-certified from the EU and the U.S.

Full Product Lifecycle Quality Control

Successfully completed nearly 100 inspections/audits
100% Pass Rate with FDA & EMA
Rigorous quality control systems in place for each stage of manufacturing:

- Quality System
- Facilities and Equipment
- Materials
- Manufacturing
- Packing and Labeling
- Laboratory Control

Commercialization

Global

A business commercialization model built for expanding internationally.

~60 countries recognize Henlius products

Efficient

Industry-leading speed in bringing medicines from the approval process to market while being highly competitive on arrival.

1,500+ in-house personnel for entire marketing and domestic sales cycle

Partnerships

International growth in key regions through commercial and R&D partnerships with leading global pharmaceutical companies.

20+ global pharmaceutical partnerships

Global Commercialization

Henlius leverages its strengths of R&D and manufacturing in China while partnering with global pharmaceutical companies to expand commercialization around the world.



FOSUN PHARMA

HLX01 (rituximab)
HLX03 (adalimumab)
China
Serplulimab (Hetronifly® in Europe)
the US, China-Hong Kong, China-Macao

Jacobson

HLX02 (trastuzumab, HERCESSI™ in the U.S., Zercepac® in Europe)
China-Hong Kong
China-Macao

Accord

HLX02 (trastuzumab, HERCESSI™ in the U.S., Zercepac® in Europe)
Over 70 countries and regions including the U.S., Canada, and Europe

Sandoz

HLX13(ipilimumab)
the U.S., 42 European countries and regions, Japan, Canada and Australia

Organon

HLX11 (pertuzumab)
HLX14 (denosumab, BILDYOS®& BILPREVDA® in the U.S. and the EU)
ex-China countries

Boston Oncology

HLX01 (rituximab)
16 countries in North Africa and other regions

Lotus

Serplulimab (Hetronifly® in Europe)
South Korea

Essex

HLX04-O (bevacizumab)
Global

Intas

Serplulimab (Hetronifly® in Europe)
Europe and India

Abbott

HLX01 (rituximab)
HLX02 (trastuzumab, HERCESSI™ in the U.S., Zercepac® in Europe)
Brazil
4 biosimilars & 1 biologic product
69 emerging markets in Asia, LAC, North Africa, etc.

KGbio

Serplulimab (Hetronifly® in Europe)
HLX02 (trastuzumab, HERCESSI™ in the U.S., Zercepac® in Europe)
10 countries in Southeast Asia including Singapore and Philippines
Serplulimab (Hetronifly® in Europe)
12 countries in North Africa and other regions

Eurofarma

HLX01 (rituximab)
HLX02 (trastuzumab, HERCESSI™ in the U.S., Zercepac® in Europe)
HLX04 (bevacizumab)
16 Latin American countries

Getz Pharma

HLX03 (adalimumab)
11 countries in Asia, Africa, Europe
HLX02 (trastuzumab, HERCESSI™ in the U.S., Zercepac® in Europe)
Certain countries in South Asia

Dr. Reddy's

HLX15 (daratumumab)
43 countries and regions in the US, Europe

Cipla

HLX02 (trastuzumab, HERCESSI™ in the U.S., Zercepac® in Europe)
Australia, New Zealand, Colombia, Malaysia

Elea

HLX02 (trastuzumab, HERCESSI™ in the U.S., Zercepac® in Europe)
Argentina, Uruguay, Paraguay

Our Products

Product portfolio and pipeline

Pre-IND / IND

- HLX316
  B7H3 x Sialidase
  Solid tumor
- HLX105
  Fusion protein
  Solid tumor
- HLX318
  BAFF x TACI x BCMA
  Autoimmune disease
- HLX37
  PD-L1 x VEGF BsAb
  Solid tumors
- HLX3901
  DLL3 x CD3 x CD28 TsAb
  SCLC
- HLX3902
  Steap1 x CD3 x CD28 TsAb
  PCa
- HLX48
  EGFR x cMet BsADC
  NSCLC, CRC
- HLX41
  LIV-1 ADC
  BC
- HLX97
  KAT6A/B
  ERα+ Breast Cancer
- HLX18 (nivolumab)
  PD-1
  Solid tumours (NSCLC, MEL, etc.)

Phase 1

- HLX6018
  GARP/TGF-β1
  IPF
- HLX701 (1)
  CD47-SIPRα Blockade
  Solid tumour
- HLX42 (2)
  EGFR ADC
  Solid tumours
- HLX43 (3) + Serplulimab (4)
  PD-L1 ADC + PD-1
  Solid tumours
- HLX05(5) (cetuximab)
  EGFR
  mCRC, HNSCC
- HLX15(6) (daratumumab)
  CD38
  Multiple myeloma
- HLX13(7) (ipilimumab)
  CTLA-4
  Melanoma, HCC, etc.
- HLX17 (pembrolizumab)
  PD-1
  NSCLC, TNBC, etc.

Phase 2

- Serplulimab (4) + HLX07 (8)
  PD-1+EGFR
  Solid tumors (sqNSCLC, etc.)
- Serplulimab (4) + HLX26 + Chemo
  PD-1+LAG-3
  NSCLC 1L
- HLX07 (8)
  EGFR
  Solid tumors (cSCC , etc.)
- HLX53 + Serplulimab (4) + bevacizumab
  TIGIT + PD-1 + VEGF
  HCC
- HLX22 (9) + T-DXd
  HER2
  HER2-low/HR+ BC
- HLX43 (3)
  PD-L1 ADC
  Solid tumours (NSCLC, etc.)
- HLX208 (10)
  BRAF V600E
  LCH/ECD, MEL, NSCLC, etc.
- HLX208 (10) + Serplulimab (4)
  BRAF V600E + PD-1
  NSCLC
- HLX79 (11) + HLX01 (rituximab) (12)
  Sialidase Fc Fusion Protein + CD20
  Active Glomerular Diseases

Phase 3

- Serplulimab (4) + Chemo
  PD-1
  ES-SCLC 1L
- Serplulimab (4) + Chemo
  PD-1
  Neo/adjuvant treatment for GC
- Serplulimab (4) + Chemo + Radio
  PD-1
  LS-SCLC 1L
- Serplulimab (4) + bevacizumab + Chemo
  PD-1+VEGF
  mCRC 1L
- HLX04-O (13)
  VEGF
  Wet AMD
- HLX22(9) + trastuzumab + Chemo
  HER2+HER2
  GC
- HLX87 (14)
  HER2 ADC
  HER2+ BC
- HLX78 (lasofoxifene) (15)
  SERM
  BC

NDA

- HLX04-O (13)
  VEGF
  Wet AMD
- HLX14 (denosumab) (16)
  RANKL
  Osteoporosis, Cancer-related bone disease, etc.
- HLX11 (pertuzumab) (17)
  HER2
  BC

In-Market

- Serplulimab (4)
  PD-1
  sqNSCLC, ES-SCLC, ESCC, nsNSCLC
- HLX01 (rituximab) (12)
  CD20
  NHL, CLL, RA (18)
- HLX02 (trastuzumab) (19)
  HER2
  BC, mGC
- HLX03 (adalimumab) (20)
  TNF-α
  RA, AS, Ps, UV, pJIA, pediatric Ps, CD, pediatric CD
- HLX04 (bevacizumab) (21)
  VEGF
  mCRC, NSCLC, GBM, HCC, EOC, FTC or PPC, CC
- BILDYOS®(denosumab) (16)
  RANKL
  Osteoporosis, etc.
- BILPREVDA® (denosumab) (16)
  RANKL
  Cancer-related bone disease, etc.
- HLX901 (neratinib) (22)
  HER1/HER2/HER4
  Extended adjuvant treatment of BC
- HLX902 (fovinaciclib)(23)
  CDK4/6
  HR+/HER2- BC

Innovative mAb · small molecule · Innovative ADC · Biosimilar mAb · Innovative fusion protein · Innovative multi-specific antibody

Bridging study in U.S. · MAA under EMA review · Approved in Global markets · BLA under FDA review · Global MRCT

(1) Exclusive rights in China (excl. Taiwan), several countries in Southeast Asia, and other selected countries and regions; Phase 1b/2a conducting in countries such as China and the U.S. (2) IND approvals obtained in China/the U.S. and granted FDA Fast Track Designation. (3) IND approvals obtained in China/the U.S./Japan/Australia (4) Approved in ~40 countries, including China, the UK, Germany, India, Singapore, trade name: Hetronifly® in Europe. Business partners: KGbio/Fosun Pharma/Intas. (5) Business partner: Shanghai Jingze. (6) Business partner: Dr. Reddy's, etc. (7) Business partner: Sandoz, etc. (8) IND approvals obtained in China/the U.S. (9) IND approvals obtained in China/the U.S./Japan/the EU. (10) Exclusive license obtained in China. (11) Exclusive license obtained in China. (12) Approved in countries such as China and Peru. The first biosimilar approved in China. Business partners: Fosun Pharma/Eurofarma/Abbott/Boston Oncology. (13) NDA under review in China. IND approvals obtained in Australia/the U.S./Singapore/EU countries, etc. Business partner: Essex. (14) The development and exclusive commercialization rights obtained in China and select ex-China markets. (15) Exclusive license obtained in China. Phase 3 MRCT enrolling globally. IND approval obtained in China. (16) Approved in the U.S. and the EU, Marketing applications under review in Canada. Business partner: Organon. (17) Marketing applications under review in China, the U.S. and the EU. Business partner: Organon. (18) The first rituximab approved for the indication in China. (19) Approved in 50+ countries, including China, U.S., the UK, Germany, France and Australia, trade name in U.S.: HERCESSI™, Trade name in Europe: Zercepac®.Business partners: Accord/ Cipla/ Jacobson/ Elea/ Eurofarma/ Abbott/ KGbio/ Getz. (20) Business partners: Fosun Wanbang/ Getz Pharma. (21) Approved in countries such as China and Bolivia. Business partners: Eurofarma. (22) Exclusive license obtained in China. (23) Commercialization in China.

Approved and Impacting the World

Serplulimab

The world's first anti-PD-1 mAb for the first-line treatment of SCLC

Indications:

- ✓ sqNSCLC
- ✓ ES-SCLC
- ✓ ESCC
- ✓ nsNSCLC

- First approved in China in 2022, followed by several Southeast Asian countries and then the EU in 2025, with authorizations now in about 40 countries and regions
- Granted ODDs by the U.S. FDA and the EC in SCLC
- Serplulimab ex-China partners include Fosun Pharma, KGbio, Intas, and Lotus
- Multiple Phase 3 MRCTs and a bridging head-to-head trial in the U.S.
- Over 5,000 subjects enrolled in China, the U.S., Japan, Spain, Germany, and other countries and regions

HLX02 Trastuzumab

Primary markets: China, US, EU

Indications:

- ✓ Early breast cancer
- ✓ Metastatic breast cancer
- ✓ Metastatic gastric cancer

- First approved in the EU, followed by China and then the US in 2024, with authorizations now in over 50 countries and regions
- Clinical results published in *BioDrugs, Cancer Chemotherapy and Pharmacology*, and ESMO
- Collaboration with global partners such as Abbott, Accord, Eurofarma, KGbio, and ELEA to enter more markets



Approved and Impacting the World

HLX14 Denosumab (BILDYOS®)

- ✓ The U.S.: approved by the FDA in Aug. 2025 for all five indications of the reference product, including osteoporosis
- ✓ The EU: approved by the EC in Sep. 2025
- ✓ Canada: NDS accepted in Sep. 2024

HLX14 Denosumab (BILPREVDA®)

- ✓ The U.S.: approved by the FDA in Aug. 2025 for all three indications of the reference product, including cancer-related bone disease
- ✓ The EU: approved by the EC in Sep. 2025
- ✓ Canada: NDS accepted in Sep. 2024

HLX01 Rituximab

- ✓ First Chinese biosimilar
- ✓ Approved in 2019

HLX03 Adalimumab

- ✓ Henlius first product to treat autoimmune diseases
- ✓ Exclusive license and collaboration agreement in 11 countries



Approved and Impacting the World

HLX04 Bevacizumab

- ✓ High-quality option for lung, colorectal and other cancers
- ✓ Approved in 2021
- ✓ Exclusive license and collaboration agreement in 15 LatAm countries, semi-exclusive in Brazil.



HLX901 Neratinib

- ✓ Reduces the risk of recurrence of early-stage HER2-positive breast cancer
- ✓ Approved in 2024

HLX902 Rituximab

- ✓ For the treatment of advanced HR+/HER2- breast cancer in patients who are initiating or have progressed on endocrine therapy
- ✓ Approved in 2025



Next in Line: Global Potential in Motion

HLX43



Cleavable tripeptide linker

- Stable in plasma & cleaved in TME, achieving dual release of payload both intracellularly(internalization)and extracellularly
- Strong bystander effect ensures payload be enriched in tumor tissues, improving the therapeutic index

Dual mechanism of action

- Synergic efficacy of ADC&immune checkpoint inhibitor(ICI)

DNA topoisomerase 1 inhibitor payload

- Strong bystander effect
- Shorter systemic half-life & higher plasma clearance rate, enabling a better safety profile

DAR~8

- Has a homogeneous and high drug-to-antibody ratio of ~8

Humanized anti-PD-L1 IgG1 mAb

- Proprietary Ab backbone with high affinity and rapid internalization rate

- Biomarker-independent ADC with IO activity, potential BIC
- Outstanding efficacy across multiple tumor types, particularly in heavily treated NSCLC and TSCC (thymic squamous cell carcinoma)
- Efficacy in various types of NSCLC (including squamous and non-squamous, with or without EGFR mutation, with or without brain/liver metastasis, PD-L1 positive and negative)
- Favorable safety profile, low hematologic toxicity
- Monotherapies and combination therapies with serplulimab are ongoing

HLX22



- Granted ODDs by the U.S. FDA and the EC in GC
- Dual-epitope HER2 therapy boosts HER2 internalisation by 40–80%, with the potential to break 1L treatment barriers in HER2+ GC
- Phase 2 shows sustained PFS/OS benefit and 80% reduction in the risk of progression or death with >2-year follow-up
- Phase 3 MRCT: head-to-head comparison vs 1L SOC (trastuzumab + chemotherapy ± pembrolizumab)
- Ongoing trial in HER2-low, HR+ breast cancer; exploratory potential in other cancers

The Future Is Ours Together

Partner with Henlius to build the future of global biopharmaceuticals that is more efficient, effective, and innovative.



Disclaimer

Henlius, the representor or the provider does not make express or implied warranties, statements or representations on the content of this document (the content of this document may also include forward-looking statements), including but not limited to the statements about the timeliness, universality and accuracy of the content for any specific purpose or with regard to the correctness of the information obtained by using the content of this document. If any conduct or consequence is caused due to any mistake, omission or incorrectness of relevant content, Henlius, the representor or the provider shall not be liable.

The content of this document does not include and shall not be deemed as any advice (including but not limited to medical advice and investment advice). You shall be liable for any decision made by yourself based on the content of this document.

Henlius

THANKS

Henlius Company Introduction
2025